


*5-HT<sub>1A</sub> receptor pharmacophores to screen for off-target activity of  $\alpha_1$ -adrenoceptor antagonists*

**Tony Ngo, Timothy J. Nicholas, Junli Chen, Angela M. Finch & Renate Griffith**

**Journal of Computer-Aided  
Molecular Design**  
Incorporating Perspectives in Drug  
Discovery and Design

ISSN 0920-654X  
Volume 27  
Number 4

J Comput Aided Mol Des (2013)  
27:305-319  
DOI 10.1007/s10822-013-9647-5



**Your article is protected by copyright and all rights are held exclusively by Springer Science +Business Media Dordrecht. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at [link.springer.com](http://link.springer.com)".**

## 5-HT<sub>1A</sub> receptor pharmacophores to screen for off-target activity of $\alpha_1$ -adrenoceptor antagonists

Tony Ngo · Timothy J. Nicholas · Junli Chen · Angela M. Finch · Renate Griffith

Received: 23 January 2013 / Accepted: 13 April 2013 / Published online: 27 April 2013  
© Springer Science+Business Media Dordrecht 2013

**Abstract** The  $\alpha_1$ -adrenoceptors ( $\alpha_1$ -ARs), in particular the  $\alpha_{1A}$ -AR subtype, are current therapeutic targets of choice for the treatment of urogenital conditions, such as benign prostatic hyperplasia (BPH). Due to the similarity between the transmembrane domains of the  $\alpha_1$ -AR subtypes, and the serotonin receptor subtype 1A (5-HT<sub>1A</sub>-R), currently used  $\alpha_1$ -AR subtype-selective drugs to treat BPH display considerable off-target affinity for the 5-HT<sub>1A</sub>-R, leading to side effects. We describe the construction and validation of pharmacophores for 5-HT<sub>1A</sub>-R agonists and antagonists. Through the structural diversity of the training sets used in their development, these pharmacophores define the properties of a compound needed to bind to 5-HT<sub>1A</sub> receptors. Using these and previously published pharmacophores in virtual screening and profiling, we have identified unique chemical compounds (hits) that fit the requirements to bind to our target, the  $\alpha_{1A}$ -AR, selectively over the off-target, the 5-HT<sub>1A</sub>-R. Selected hits have been obtained and their affinities for  $\alpha_{1A}$ -AR,  $\alpha_{1B}$ -AR and 5-HT<sub>1A</sub>-R determined in radioligand binding assays, using membrane preparations which contain human receptors expressed individually. Three of the tested hits demonstrate statistically significant selectivity for  $\alpha_{1A}$ -AR over 5-HT<sub>1A</sub>-R. All seven tested hits bind to  $\alpha_{1A}$ -AR, with two compounds displaying  $K_i$  values below 1  $\mu$ M, and a further two  $K_i$  values of around 10  $\mu$ M. The insights and knowledge

gained through the development of the new 5-HT<sub>1A</sub>-R pharmacophores will greatly aid in the design and synthesis of derivatives of our lead compound, and allow the generation of more efficacious and selective ligands.

**Keywords** Pharmacophore · 5-HT<sub>1A</sub> receptor ·  $\alpha_1$ -Adrenergic receptors · Drug selectivity · Radioligand binding · GPCR

### Introduction

The monoamine receptors belong to the G protein-coupled receptor (GPCR) superfamily. Members of this class of receptors were originally classified based on their affinity for endogenous monoamine ligands, such as norepinephrine, serotonin and dopamine, in addition to their systemic distribution [1]. These receptors function via the transmission of an extracellular stimulus through their seven transmembrane helices to intracellular loops that then facilitate the activation of signalling proteins [2]. Collectively, they play a crucial role in the physiology of the cardio-pulmonary, renal, urogenital, gastrointestinal and central nervous systems [3–6]. Pharmacologically, this makes these receptors targets for the treatment of a number of pathological conditions including hypertension, benign prostatic hyperplasia (BPH), prostate cancer, schizophrenia and depression [7–12]. However, owing to the similarity in structure of their endogenous ligands, the binding pockets of these receptors are highly similar, with members across the three families sharing up to 50 % amino acid sequence identity [13–15]. Thus many clinically used drugs unintentionally exhibit high affinity for other monoamine receptors outside of their intended therapeutic target [16]. Due to the wide systemic distribution of these receptors,

---

Tony Ngo and Timothy J. Nicholas have contributed equally.

---

T. Ngo · T. J. Nicholas · J. Chen · A. M. Finch · R. Griffith (✉)

Department of Pharmacology, School of Medical Sciences, The University of New South Wales, UNSW Sydney, NSW 2052, Australia  
e-mail: r.griffith@unsw.edu.au

this can result in a number of side effects, dependent on the drug's off-target receptor interactions.

The  $\alpha_1$ -adrenoceptors ( $\alpha_1$ -ARs) respond to the biogenic amines norepinephrine and epinephrine [17]. Three  $\alpha_1$ -AR subtypes have been identified with the  $\alpha_{1A}$  subtype expressed predominately in prostate and urethral smooth muscle [18], whilst the  $\alpha_{1B}$  subtype is predominately located in the smooth muscle of skeletal and mesenteric arteries of older men [19]. Knowledge of the localization of the  $\alpha_{1D}$  subtype is currently limited due to its low level of cell surface expression and a limited number of selective small molecule ligands capable of activating or antagonizing this receptor [20]. The  $\alpha_{1A}$  subtype is the current therapeutic target of choice for the treatment of BPH. Selective antagonism of this receptor has been demonstrated to improve urine flow rate, and relieve lower urinary tract symptoms associated with this disease [9, 21]. In addition, antagonism of the  $\alpha_{1B}$ -ARs reduces arterial and venous vasoconstriction and consequently decreases peripheral resistance, lowering arterial blood pressure in hypertensive patients [11].

The difficulty in developing a ligand with  $\alpha_1$ -AR subtype selective properties is compounded by the similarity between the transmembrane domains of the  $\alpha_1$ -ARs, and the serotonin receptor subtype 1A (5-HT<sub>1A</sub>-R) [14]. It has been demonstrated that the two most prevalently used  $\alpha_1$ -AR selective drugs for the treatment of BPH (tamsulosin and naftopidil) show no selectivity between their intended target (the  $\alpha_{1A}$ -AR) and the 5-HT<sub>1A</sub>-R [22, 23]. Furthermore, several other  $\alpha_1$ -AR subtype selective compounds such as BMY7378, which is selective for the  $\alpha_{1D}$ -AR over the  $\alpha_{1A}$  and  $\alpha_{1B}$ -AR, have been demonstrated to have no selectivity for the  $\alpha_{1D}$ -AR over the 5-HT<sub>1A</sub>-R [14].

The 5-HT<sub>1A</sub>-R acts primarily as a presynaptic autoreceptor, regulating neurotransmitter release across the synaptic junction [24]. Interference with its actions is known to deregulate sleep patterns, cause anxiety like behaviour and interrupt neural tone to the iris sphincter muscle [25–27]. Systemic interference with 5-HT<sub>1A</sub>-R signalling may also lead to sexual dysfunction and inhibited bladder control [28]. Thus it represents an important off-target to avoid in the design of next generation  $\alpha_1$ -AR ligands.

There is at present no crystal structure for any of the  $\alpha_1$ -ARs or the 5-HT<sub>1A</sub>-R, thus identifying differences between these receptors that may be manipulated in order to design a more  $\alpha_1$ -AR selective drug is limited to ligand-based structure–activity studies and in silico methodologies such as pharmacophore modelling. We have previously developed pharmacophores for selective antagonists at the  $\alpha_1$ -AR subtypes [29], these will be used in the current work and will be referred to as “ $\alpha_{1X}$ -AR pharmacophore” (X can be A, B, or D) for short. We have also demonstrated their usefulness for retrieving novel compounds with

micromolar  $\alpha_{1A}$ -AR affinities and some subtype selectivity through in silico database screening [30]. Current 5-HT<sub>1A</sub>-R pharmacophores are restricted in multiple aspects of their design. Training sets are limited to derivatives of only one class of chemical compounds, typically arylpiperazine based ligands [31–33], thus limiting their predictive power for other classes of compounds that may show 5-HT<sub>1A</sub>-R affinity. Additionally, no pharmacophores for the  $\alpha_1$ -ARs or 5-HT<sub>1A</sub>-R at present have been designed to include areas that a ligand cannot occupy for steric reasons (excluded volumes).

Therefore our aim is to construct 5-HT<sub>1A</sub>-R pharmacophore models that will identify multiple classes of chemical compounds with 5-HT<sub>1A</sub>-R affinity. Secondly, we aim to validate the predictive power of these pharmacophores by determining in vitro the 5-HT<sub>1A</sub>-R,  $\alpha_{1A}$ -AR and  $\alpha_{1B}$ -AR affinities of novel compounds selected from in silico screening and profiling with these pharmacophores.

## Materials and methods

### Materials

Test compounds were obtained from the Developmental Therapeutics Program of the National Cancer Institute (USA) (compounds (48), (51)–(57)) and Tripos, Inc. (England) (compounds (49) and (50)). All test compounds were solubilized in dimethyl sulfoxide (DMSO) at 10 mM concentration and stored at  $-80^\circ\text{C}$ . 5-methylurapidil, BMY7378 hydrochloride, phentolamine methanesulfonate and serotonin hydrochloride were purchased from Sigma-Aldrich (St. Louis, Missouri). Tamsulosin hydrochloride was supplied by Tocris Bioscience (Bristol, UK). [<sup>3</sup>H]-OH-DPAT (226 Ci mmol<sup>-1</sup>) was purchased from GE Healthcare (Uppsala, Sweden) and [<sup>3</sup>H]prazosin (85 Ci mmol<sup>-1</sup>) from Perkin Elmer (Waltham, Massachusetts). Chemicals used in buffered solutions were from Ajax Finechem (Cheltenham, Australia) and were of the highest purity available.

### Pharmacophore modelling

Training sets for the two pharmacophore models were derived from published reports containing 5-HT<sub>1A</sub>-R agonists or 5-HT<sub>1A</sub>-R antagonists. Compounds were chosen from studies where  $K_i$  values were obtained from radioligand competition assays using human recombinant receptors expressed in cell lines. All compounds were built using ChemBioDraw Ultra version 12 (CambridgeSoft, [www.cambridgesoft.com](http://www.cambridgesoft.com)) and imported into Discovery Studio Client (DS) versions 2–3.5 (Accelrys Inc., San Diego, CA, USA), or sketched directly in DS. Conformers of each

compound were generated as described earlier [29] in DS using the 'BEST' conformational search and a 20 kcal/mol energy threshold as recommended for pharmacophore development [34].

Hypotheses were generated using the HypoGen algorithm, which allows a maximum of five different features in pharmacophore generation. The features chosen were hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), general hydrophobic (HY), hydrophobic aromatic (Har) and the positive ionisable feature (PI). The latter describes a feature such as a basic nitrogen, likely to be protonated at physiological pH, and thus capable of forming an ionic interaction. For each training set ten hypotheses were generated with and without considering excluded volumes.

#### Ligand mapping and database screening

Test compounds were mapped to the resulting best pharmacophores following conformer generation as described above. In order to attain a predicted affinity value, each compound was allowed to miss one pharmacophore feature in its mapping.

The NCI2000 database containing 238,819 compounds was screened against the  $\alpha_{1A}$ -AR pharmacophore using the DS protocol 'Search 3D database' to generate a hit list of compounds fitting onto the  $\alpha_{1A}$ -AR pharmacophore. The hits obtained from the NCI2000 database screening were subsequently profiled against the  $\alpha_{1A}$ ,  $\alpha_{1B}$ ,  $\alpha_{1D}$ -AR, 5-HT<sub>1A</sub>-R agonist and 5-HT<sub>1A</sub>-R antagonist pharmacophores using the 'Ligand Profiler' protocol in order to retrieve compounds which specifically fit only to the  $\alpha_{1A}$ -AR pharmacophore. The 'Ligand Profiler' gives a FitValue of each compound to the respective pharmacophore between 0.0 and 1.0, where 1.0 means 100 % fit. After obtaining FitValues, we considered only compounds which had high FitValues for the  $\alpha_{1A}$ -AR pharmacophore and zero FitValues for the  $\alpha_{1B}$ -AR,  $\alpha_{1D}$ -AR, 5-HT<sub>1A</sub>-R agonist and 5-HT<sub>1A</sub>-R antagonist pharmacophores.

#### Expression of cloned genes in COS-1 cells and membrane preparation

COS-1 cells (American Type Culture Collection, Manassas, VA) were maintained using standard culturing techniques. Transient expression of human 5-HT<sub>1A</sub>-R and  $\alpha_1$ -AR cDNA obtained from the Missouri S&T cDNA Resource Center ([www.cdna.org](http://www.cdna.org)) in COS-1 cells was achieved using diethylaminoethane-dextran (DEAE-dextran) methodology as previously described [35]. Membrane preparations were made from COS-1 cells transiently expressing the receptor of interest as previously described

[36] and protein concentration was determined by the Bradford method [37].

#### Radioligand binding experiments

Receptor binding assays were performed as previously described [30].

##### 5-HT<sub>1A</sub>-R binding

Ligands and membrane preparations were suspended in 50 mM Tris-HCl and 4 mM CaCl<sub>2</sub>, pH 7.4. In saturation experiments, 5-HT<sub>1A</sub>-R containing membrane was incubated with varying concentrations of [<sup>3</sup>H]-OH-DPAT (0.5–16 nM). Competition experiments contained membrane incubated with [<sup>3</sup>H]-OH-DPAT (1 nM) and increasing concentrations of test compounds. Nonspecific binding was defined as binding in the presence of 10  $\mu$ M serotonin.

##### $\alpha_1$ -AR binding

Ligands and membrane preparations were suspended in 20 mM HEPES, 1.4 mM EGTA and 12.5 mM MgCl<sub>2</sub>, pH 7.4. For saturation experiments,  $\alpha_{1A}$  and  $\alpha_{1B}$ -ARs were incubated with varying concentrations of [<sup>3</sup>H]prazosin (0.125–16 nM). In competition experiments,  $\alpha_{1A}$  and  $\alpha_{1B}$ -ARs were incubated with 0.2 nM [<sup>3</sup>H]prazosin and increasing concentrations of test compounds. Nonspecific binding was defined as binding in the presence of 100  $\mu$ M phentolamine.

#### Data analysis

In generating pharmacophore hypotheses, Catalyst analyses statistical validity using three parameters: the correlation ( $R^2$ ) between real and estimated affinities of compounds; the configuration cost, which describes the total hypothesis space and should have a value less than 17 to ensure all possibilities have been considered; and thirdly the difference in total costs between generated hypotheses and the null hypothesis. The null cost is the cost of a hypothesis that would give no correlation between the predicted and experimental activities [38]. Costs are expressed in units of bits.

Nonlinear regression analysis of saturation and competition binding assay data was performed using the curve fitting program GraphPad Prism (San Diego, CA, USA). The  $K_i$  values for each compound tested were produced by transformation of the program-calculated IC<sub>50</sub> value (concentration of ligand resulting in 50 % inhibition of radioligand binding) via the Cheng-Prusoff equation  $K_i = IC_{50} / (1 + ([L]/K_D))$ ; where [L] is 0.2 nM [<sup>3</sup>H]prazosin (ARs) or

1 nM [ $^3\text{H}$ ]-OH-DPAT (5-HT<sub>1A</sub>-R) and  $K_D$  is the dissociation constant of L. The competitive binding data for each ligand was tested for both one- and two-site binding. A one-site binding model was determined as the appropriate form of analysis for all binding data. Statistically significant differences ( $p < 0.01$ ) between the affinities of all compounds for the  $\alpha_1$ -AR subtypes and the 5-HT<sub>1A</sub>-R were determined using one way ANOVA and the Student–Newman–Keuls multiple comparison test.

## Results

### Pharmacophore training set construction

Compounds were chosen such that each training set contained high chemical diversity and affinity values ranging over 3.5 orders of magnitude (Table 1). This was in order to ensure representation of the known classes of chemical compounds that interact with each receptor in each training set. In total, 46 compounds were gathered from the literature and classified into two specific training sets: 5-HT<sub>1A</sub>-R agonists (Table 2) and 5-HT<sub>1A</sub>-R antagonists (Table 3).

### Pharmacophore generation

Pharmacophore hypotheses were constructed for each training set using the features general hydrophobic (HY), hydrophobic aromatic (Har), hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), and ionic interactions (PI). The ten top-ranked hypotheses were first generated without considering steric hindrance, and then were re-generated to consider the impact of steric hindrance by allowing for the inclusion of up to 10 excluded volume features (EX). Each EX represents a sphere in the vicinity of the ligand where additional ligand bulk leads to a lower affinity. Consideration of these “steric clashes” can improve the accuracy of a hypothesis to distinguish between active and inactive agents [39]. The most statistically valid pharmacophore models with EXs were selected.

A basic amine (PI feature) is known to be essential for the binding of compounds to both the 5-HT<sub>1A</sub>-R and  $\alpha_1$ -ARs [40–42], therefore the inclusion of a PI feature was

forced in hypothesis generation. This was previously [29] found to improve correlation, particularly for high affinity compounds, and was considered a valid approach for generating the best pharmacophore models.

For 5-HT<sub>1A</sub>-R agonist pharmacophore generation the highest ranked hypothesis was a model consisting of 1 PI, 1 HBA, 3 HY features and 7 EXs (Fig. 1a). The statistical parameters associated with pharmacophore generation are provided in Table 1. With a configuration cost of 15, a correlation of 0.85 between the actual and the predicted affinities of the training set compounds, and a difference between the null and the hypothesis cost of 75, there is a >90 % statistical probability that this hypothesis represents a real correlation with biological activity [38].

The highest ranked hypothesis for the 5-HT<sub>1A</sub>-R antagonist pharmacophore consisted of 1 PI, 1 HBA, 1 HY and 1 Har features and 5 EXs (Fig. 1b). The configuration cost was 14, the correlation 0.83 and the cost differential 41 (Table 1), indicating a 75 % statistical probability that this hypothesis represents a real correlation with biological activity [38].

### Ligand pharmacophore mappings

Using the pharmacophores, known  $\alpha_1$ -AR ligands with 5-HT<sub>1A</sub>-R affinity were mapped and affinities predicted. For consistency and to enable comparisons between predictions, these mappings are performed in a slightly different way to the way ligands are mapped and predicted during the pharmacophore generation runs. Based on their known  $K_i$  values, the affinities of BMY7378, 5-methylurapidil and tamsulosin are generally underpredicted in these mapping runs (Table 4). It should be acknowledged that 5-methylurapidil was part of the 5-HT<sub>1A</sub>-R agonist training set, and tamsulosin was part of the 5-HT<sub>1A</sub>-R antagonist training set, and their predicted affinities are much higher when using the correct pharmacophore (agonist vs. antagonist pharmacophore) for mapping. Tamsulosin is correctly predicted to have the highest affinity for the  $\alpha_1$ -AR. The 5-HT<sub>1A</sub>-R agonist BMY7378 is predicted to display similar affinity by the agonist and the antagonist pharmacophores.

Three novel compounds previously identified by  $\alpha_1$ -AR pharmacophores (compounds (48)–(50)) [29], and



















**Table 1** Summary of pharmacophore statistical parameters

Pharmacophore	Training set compounds	Range of affinity, $K_i$ (nM)	Correlation ( $R^2$ ) <sup>a</sup>	Cost difference <sup>b</sup>
5-HT <sub>1A</sub> -R agonist	24	0.03–50,000	0.85	75
5-HT <sub>1A</sub> -R antagonist	22	0.2–10,000	0.83	41





















<sup>a</sup> Refers to the correlation between predicted and actual affinity of compounds in the training set, for the highest ranked hypothesis

<sup>b</sup> Refers to the difference between the cost of the highest ranked hypothesis and the null cost


**Table 2** Structure and composition of 5-HT<sub>1A</sub> agonist pharmacophore training set

Compound scaffolds								
								
<b>(R) 8-OH-DPAT</b>	<b>Quetiapine</b>	<b>Olanzapine</b>	<b>Ziprasidone</b>	<b>5-Methylurapidil</b>				
								
<b>(±)BMY14802</b>	<b>JB788</b>	<b>S14671</b>	<b>(A)</b>					
								
<b>(B)</b>	<b>(C)</b>	<b>(D)</b>	<b>(E)</b>					
Compound, [Reference]	K <sub>i</sub> (nM)	Scaffold, Substituents	Compound, [Reference]	K <sub>i</sub> (nM)	Scaffold, Substituents	Compound, [Reference]	K <sub>i</sub> (nM)	Scaffold, Substituents
(R) 8-OH-DPAT (1) [63]	1.3	–	F15599 (9) [64]	2.69	<b>A</b> X= N Y= CH R <sub>1</sub> =CH <sub>3</sub> R <sub>2</sub> =H	(17) [55]	1.25	 <b>C</b> R=
Quetiapine (2) [65]	250	–	F13714 (10) [64]	0.04	<b>A</b> X=Y=CH R <sub>1</sub> = CH <sub>3</sub> R <sub>2</sub> = -NHMe	(18) [55]	11.2	 <b>C</b> R=
Olanzapine (3) [65]	1637	–	(11) [66]	7.4	<b>A</b> X=Y=CH R <sub>1</sub> = CH <sub>2</sub> OH R <sub>2</sub> =H	(19) [67]	15.8	<b>D</b> (±) R <sub>1</sub> = <i>n</i> -Pr R <sub>2</sub> = 5-OCH <sub>3</sub>
Ziprasidone (4) [65]	1.24	–	(12) [66]	66	<b>A</b> X=CH Y=N R <sub>1</sub> =CH <sub>3</sub> R <sub>2</sub> =H	(20) [67]	210	<b>D</b> (±) R <sub>1</sub> = <i>n</i> -Pr R <sub>2</sub> = 4,5- 
5-Methylurapidil (5) [46]	0.06	–	(13) [66]	10 000	<b>A</b> X=Y=CH R <sub>1</sub> = COOH R <sub>2</sub> =H	(21) [67]	50 000	<b>D</b> (±) R <sub>1</sub> = H R <sub>2</sub> = 4,5- 
BMY14802 (6) [65]	62.8	–	(14) [52]	1.02	<b>B</b> X= S R= 2-OCH <sub>3</sub>	(22) [68]	0.30	<b>E</b> R <sub>1</sub> -R <sub>2</sub> = -(CH <sub>2</sub> ) <sub>2</sub> - R = 
JB788 (7) [69]	0.80	–	(15) [52]	53.7	<b>B</b> X= O R= 2,6-diOCH <sub>3</sub>	(23) [68]	1.34	<b>E</b> R <sub>1</sub> -R <sub>2</sub> = -(CH <sub>2</sub> ) <sub>2</sub> - R = 
S14671 (8) [65]	0.03	–	(16) [52]	1000	<b>B</b> X= O R= 4-C <sub>6</sub> H <sub>5</sub>	(24) [68]	34	<b>E</b> R <sub>1</sub> ,R <sub>2</sub> = H R = 

**Table 3** Structure and composition of 5-HT<sub>1A</sub> antagonist pharmacophore training set

Compound scaffolds					
					
<b>WAY100635</b>	<b>Tamsulosin</b>	<b>NAN-190</b>			
					
<b>(A)</b>	<b>(B)</b>	<b>(C)</b>	<b>(D)</b>		
					
<b>(E)</b>	<b>(F)</b>	<b>(G)</b>			
Compound, [Reference]	K <sub>i</sub> (nM)	Scaffold, substituents	Compound, [Reference]	K <sub>i</sub> (nM)	Scaffold, substituents
WAY100635 (25) [70]	2.2	–	(36) [71]	13	<b>C</b> X= N 
Tamsulosin (26) [72]	0.79	–	(37) [71]	320	<b>C</b> X= N 
NAN-190 (27) [73]	2.14	–	(38) [74]	1.3	<b>D</b> Ar = 4-Indole R <sub>1</sub> = 
(28) [75]	0.2	<b>A</b> R= 	(39) [74]	94	<b>D</b> Ar = 4-Indole R <sub>1</sub> = H R <sub>2</sub> = cyclohexyl
(29) [75]	0.7	<b>A</b> R = 	(40) [74]	3000	<b>D</b> Ar = 5-Indole (±)R <sub>1</sub> = OH R <sub>2</sub> = cyclohexyl
(30) [75]	24	<b>A</b> R = 	(41) [63]	31	<b>E</b> R = CH <sub>3</sub>
(31) [75]	428	<b>A</b> R = 	(42) [63]	1210	<b>E</b> R = OH
(32) [76]	0.25	<b>B</b> R = 	(43) [10]	0.93	<b>F</b> R <sub>1</sub> = H R <sub>2</sub> = H R <sub>3</sub> = Pr
(33) [76]	51	<b>B</b> 	(44) [10]	196	<b>F</b> R <sub>1</sub> = F R <sub>2</sub> = Pr R <sub>3</sub> = cyclobutyl
(34) [76]	10 000	<b>B</b> R = 	(45) [77]	37	<b>G</b> (cis) 
(35) [71]	0.32	<b>C</b> X= C R = 	(46) [77]	147	<b>G</b> (cis) 

**Fig. 1** 5-HT<sub>1A</sub>-agonist (a) and 5-HT<sub>1A</sub>-antagonist (b) pharmacophore models and comparison (c). The three dimensional pharmacophore is shown on the left, and a 2D representation on the right in a and b. The most active ligand in each training set has been mapped on to the respective pharmacophore using stick representation. The atoms are colour coded as follows: carbon (grey), hydrogen (white), oxygen (red), nitrogen (blue). The red spheres represent the location which a positive ionisable group (basic nitrogen) should occupy, the green spheres map the projection path of a hydrogen bond acceptor. The cyan spheres represent general hydrophobic groups and the light blue sphere represents aromatic hydrophobic groups. The grey spheres represent excluded volumes that a ligand cannot occupy. The two pharmacophores have been superimposed in panel c. Some features of the antagonist pharmacophore have been recoloured for clarity: excluded volumes are black, the hydrogen bond acceptor is dark green, the positive ionisable group is dark red, and the hydrophobic and aromatic hydrophobic features are dark blue









confirmed in vitro to have  $\alpha_1$ -AR affinity at rodent receptors [30] were predicted by all pharmacophores to have affinity for the human receptors (Table 4). In all cases, the lowest affinity was predicted for the  $\alpha_{1B}$ -AR, which mirrors the observed  $\alpha_{1A/D}$ -AR selectivity over  $\alpha_{1B}$ -AR (for rodent  $\alpha_1$ -ARs). These compounds had been selected for this potential, and had not previously been mapped to the 5-HT<sub>1A</sub>-R pharmacophores, where they are predicted to display similar, or even better affinities than at the  $\alpha_{1A}$ -AR.

The predicted and experimentally determined selectivities of the compounds described in Table 4 are presented in

Table 5. Selectivity for  $\alpha_{1A}$  over  $\alpha_{1B}$ -AR is correctly predicted for tamsulosin (26), for (48) and for (50), although the magnitude of this selectivity is not predicted correctly for (50). Compound (49) is predicted to show threefold selectivity for  $\alpha_{1A}$  over  $\alpha_{1B}$ -AR, but this was not observed experimentally (similar affinity for the two rodent receptors). The 35-fold and twofold selectivities of (5) and (47) for the  $\alpha_{1A}$  over  $\alpha_{1B}$ -AR are not predicted correctly. Selectivity for  $\alpha_{1A}$ -AR over 5-HT<sub>1A</sub>-R is predicted correctly for (26), and for 5-HT<sub>1A</sub>-R over  $\alpha_{1A}$ -AR for (5) and (47).

**Table 4** 5-HT<sub>1A</sub>-R and  $\alpha_1$ -AR pharmacophore predicted and experimentally determined affinity of experimental compounds

Compound	Structure	Pharmacophore predicted affinity $K_i$ (nM)				Experimental affinities $K_i$ (nM) <sup>d</sup>		
		5-HT <sub>1A</sub> -R agonist	5-HT <sub>1A</sub> -R antagonist	$\alpha_{1A}$ -AR	$\alpha_{1B}$ -AR	5-HT <sub>1A</sub> -R [Reference]	$\alpha_{1A}$ -AR [Reference]	$\alpha_{1B}$ -AR [Reference]
5-Methylurapidil ( <b>5</b> )		0.65	64	105	77	0.06 [46]	0.98 [78]	33.9 [78]
BMY7378 ( <b>47</b> )		25	20	40	8.5	1.26 [14]	380 [14]	708 [14]
Tamsulosin ( <b>26</b> )		11	2.8	2.4	10	0.79 [72]	0.13 [72]	1.92 [72]
NSC 134750 <sup>a,b</sup> ( <b>48</b> )		(R) 1,100 (S) 53	(R) 460 (S) 420	(R) 1,100 (S) 1,300	(R) 2,100 (S) 1,700	N/A	2,000 <sup>e</sup> [30]	11,800 <sup>e</sup> [30]
Tripos 01572 <sup>a,c</sup> ( <b>49</b> )		(R) 0.32 (S) 0.63	(R) 110 (S) 200	(R) 5.7 (S) 8.9	(R) 19 (S) 27	N/A	1,170 <sup>e</sup> [30]	1,420 <sup>e</sup> [30]
Tripos 09931 <sup>c</sup> ( <b>50</b> )		1.5	65	13	62,000	N/A	490 <sup>e</sup> [30]	4,590 <sup>e</sup> [30]

<sup>a</sup> Unknown stereochemistry. Both enantiomers were mapped to the pharmacophores. Values for both enantiomers are given

<sup>b</sup> NSC refers to the National Institute of Cancer database code

<sup>c</sup> Tripos database code

<sup>d</sup> References indicated in square brackets

<sup>e</sup> Determined using rodent receptors

**Table 5** Predicted and experimentally determined selectivities of experimental compounds

Compound	Pharmacophore predicted selectivity (fold) <sup>d</sup>			Experimental selectivity (fold) <sup>d</sup>	
	$\alpha_{1A}$ -AR over $\alpha_{1B}$ -AR	$\alpha_{1A}$ -AR over 5-HT <sub>1A</sub> -R agonist	$\alpha_{1A}$ -AR over 5-HT <sub>1A</sub> -R antagonist	$\alpha_{1A}$ -AR over $\alpha_{1B}$ -AR	$\alpha_{1A}$ -AR over 5-HT <sub>1A</sub> -R
5-Methylurapidil ( <b>5</b> )	0.7	0.006	0.6	35	0.06
BMY7378 ( <b>47</b> )	0.2	0.6	0.5	2	0.003
Tamsulosin ( <b>26</b> )	4	5	1	15	6
NSC 134750 <sup>a,b</sup> ( <b>48</b> )	(R) 2 (S) 1	(R) 1 (S) 0.04	(R) 0.4 (S) 0.3	6	
Tripos 01572 <sup>a,c</sup> ( <b>49</b> )	(R) 3 (S) 3	(R) 0.06 (S) 0.07	(R) 20 (S) 20	1	
Tripos 09931 <sup>c</sup> ( <b>50</b> )	5,000	0.12	5	9	

<sup>a</sup> Unknown stereochemistry. Both enantiomers were mapped to the pharmacophores. Values for both enantiomers are given

<sup>b</sup> NSC refers to the National Institute of Cancer database code

<sup>c</sup> Tripos database code

<sup>d</sup> 1/ratio of  $K_i$  values presented in Table 4

### Database screening and compound selection

Our published  $\alpha_{1A}$ -AR pharmacophore [29] was used to search the NCI2000 database, containing 238,819 compounds, yielding 7,539 hits (3.2 % of the database). The 'Ligand Profiler' protocol was then used in order to select

compounds which showed a good fit on the  $\alpha_{1A}$ -AR pharmacophore and did not fit onto any of the other pharmacophores ( $\alpha_{1A}$ ,  $\alpha_{1B}$ ,  $\alpha_{1D}$ -AR, 5-HT<sub>1A</sub>-R agonist and 5-HT<sub>1A</sub>-R antagonist pharmacophores). Using this method, it was determined that there were 168 unique  $\alpha_{1A}$ -AR hits with fits of higher than 0.7 (0.07 % of the whole database).

**Table 6** Ligand Profiler results

NSC code	Relative fit to $\alpha_{1A}$ -AR pharmacophore	MW	Comments
276751	0.944	429	No screening data available; novel structure; requested
152009	0.911	599	Excluded: too large
135759	0.903	459	No screening data available; novel structure; requested
111066	0.900	489	No screening data available. Excluded: highly similar to 135759


Compounds were selected from the top, in order of  $\alpha_{1A}$ -AR pharmacophore fit value, taking into account structural novelty, as well as size. Table 6 illustrates this process for the top four hits from Ligand Profiler, with the next three unique hits in the list also excluded based on their similarity to hits already selected. Figure 2 provides the structures of the selected compounds, and indicates which ones were available to be tested, as well as their NSC code and relative fit value to the  $\alpha_{1A}$ -AR pharmacophore. A reference describing the synthesis of (52) for an unrelated use was retrieved [43]. No further references to any of the compounds were found. The identity of each

tested hit was confirmed and its purity estimated from liquid chromatography/mass spectrometry (LCMS).


Screening with previous, preliminary pharmacophores (data not shown) had retrieved a further three compounds, and their structures and details are provided in Fig. 3. Despite their lower Ligand Profiler fits to the  $\alpha_{1A}$ -AR pharmacophore, it was decided to test these three compounds in vitro, as well. (55) in particular is an analogue of our previous lead compound (48) and appeared to be very pure. Two references were found for (56), dealing with Hsp90 inhibitors and with its synthesis. This compound is structurally novel as an  $\alpha_1$ -AR ligand, although its 8-aminoquinoline unit is related to the amino-substituted quinazoline unit found in prazosin and related  $\alpha_1$ -AR antagonists, and a 4-aminoquinoline unit is found in one unique class of dimeric  $\alpha_1$ -AR ligands [44]. All three compounds, (55)–(57), did not fit onto any of the other pharmacophores ( $\alpha_{1A}$ ,  $\alpha_{1B}$ ,  $\alpha_{1D}$ -AR, 5-HT<sub>1A</sub>-R agonist and 5-HT<sub>1A</sub>-R antagonist pharmacophores).

Evaluation of compound affinity at recombinant human  $\alpha_{1A}$  and  $\alpha_{1B}$ -ARs and 5-HT<sub>1A</sub>-R

Compounds were evaluated for ligand binding characteristics on membrane-expressed  $\alpha_{1A}$ -ARs ( $K_D = 0.432 \pm$



**Fig. 2** Structures of hits selected for testing. Fit refers to the relative fit to the  $\alpha_{1A}$ -AR pharmacophore. Percentages refer to estimated compound purity. See text for details



**Fig. 3** Structures of additional tested compounds. Fit refers to the relative fit to the  $\alpha_{1A}$ -AR pharmacophore. Percentages refer to estimated compound purity. See text for details

0.187 nM,  $n = 3$ ) and  $\alpha_{1B}$ -ARs ( $K_D = 0.162 \pm 0.045$  nM,  $n = 3$ ) in competition radioligand binding studies using [ $^3$ H]-prazosin and membrane-expressed 5-HT $_{1A}$ -R ( $K_D = 1.40 \pm 0.07$  nM,  $n = 3$ ) using [ $^3$ H]-OH-DPAT. All curves displayed sigmoidal binding, with a Hill slope for all curves not significantly different from 1 ( $p < 0.05$ ).

The affinity values obtained for 5-methylurapidil, BMY7378 and tamsulosin fell within the range of reported values in the literature [14, 45–47], and the documented  $\alpha_{1A}$ -AR selectivity of 5-methylurapidil (over  $\alpha_{1B}$ -AR) was also observed (Table 7). Three compounds ((48), (49) and (50)) previously identified using our  $\alpha_1$ -AR subtype selective pharmacophores [30] were tested on human  $\alpha_{1A}$  and  $\alpha_{1B}$ -ARs and 5-HT $_{1A}$ -R. (48) exhibited low micromolar affinity for human  $\alpha_{1A}$  and  $\alpha_{1B}$ -ARs (Table 7), consistent with values obtained using rat receptors [30]; however the  $\alpha_{1A}$ -AR selectivity seen with rodent receptors was reduced [30]. Both (48) and (49) exhibited low micromolar affinity ( $K_i < 3$   $\mu$ M) for the 5-HT $_{1A}$ -R, similar to their affinity for the rat and/or human  $\alpha_{1A}$ -AR (Tables 4, 7). Moderate affinity was observed for (50) ( $K_i$  22  $\mu$ M) at the 5-HT $_{1A}$ -R, whereas it displayed relatively higher affinity at the rat  $\alpha_{1A}$ -AR ( $K_i$  490 nM). In terms of selectivity, (48) and (49) were predicted to display a small preference for the  $\alpha_{1A}$ -AR over the  $\alpha_{1B}$ -AR, with a 5,000-fold preference predicted for (50) (Table 5). This was verified experimentally for (48) (Table 7). Predictions of selectivity between  $\alpha_{1A}$ -AR and 5-HT $_{1A}$ -R are much more difficult to assess for these three compounds, because they vary widely between the 5-HT $_{1A}$ -R agonist and antagonist pharmacophores (Table 5).

The hit compounds identified by the screen described above ((51)–(54)), as well as with the preliminary pharmacophores ((55)–(57)), all had some affinity for the  $\alpha_{1A}$ -AR, with (51) ( $K_i = 192$  nM) and (57) ( $K_i = 209$  nM)

binding with nanomolar affinity. All seven hit compounds identified ((51)–(57)) were chosen because their relative fits in the Ligand Profiler screen were zero for the  $\alpha_{1B}$ -AR and 5-HT $_{1A}$ -R. However, their affinity at the  $\alpha_{1B}$ -AR was similar to that at the  $\alpha_{1A}$ -AR. Affinity at the 5-HT $_{1A}$ -R was also generally similar, however, compound (57) displayed statistically significant (about 40 fold),  $p < 0.05$  preference for the  $\alpha_{1A}$ -AR over the 5-HT $_{1A}$ -R, compound (53) about tenfold preference, and compounds (52) and (54) displayed around fourfold preference for the  $\alpha_{1A}$ -AR over the 5-HT $_{1A}$ -R. On the other hand, compounds (55) and (56) display statistically significant preferences for the 5-HT $_{1A}$ -R over the  $\alpha_{1A}$ -AR.

## Discussion

The discovery of novel, high affinity  $\alpha_{1A}$ -AR selective antagonists is essential to the development of more efficacious drugs for urogenital conditions [11, 48, 49]. We have previously constructed pharmacophores that were successfully able to identify  $\alpha_1$ -AR subtype selective antagonists suitable for drug development [29, 30]. Currently, clinically used  $\alpha_{1A}$ -AR selective antagonists have significant off-target affinity for the 5-HT $_{1A}$ -R [22, 46], which contributes to their side effect profile [50]. Therefore, it was now of interest to develop pharmacophores capable of predicting and thus filtering out hit compounds with significant affinity for the 5-HT $_{1A}$ -R.

Through constructing structurally diverse training sets, pharmacophores were developed for 5-HT $_{1A}$ -R agonists and antagonists, with each exhibiting high correlation in terms of predicted versus actual activity ( $R^2 > 0.8$ ) for the training set compounds. When superimposed on to one another (Fig. 1c), a high degree of similarity is observed between the 5-HT $_{1A}$ -R agonist and antagonist pharmacophores. There is close to identical positioning of both the PI and HBA features, with one of the hydrophobic features of the agonist pharmacophore close to the two hydrophobic features of the antagonist pharmacophore and some of the excluded volumes also located in close proximity. However, the agonist pharmacophore extends beyond this cluster of features with two closely spaced hydrophobic features. The features selected in these pharmacophores correspond to the interactions shown to be crucial for 5-HT $_{1A}$ -R ligand binding in mutagenesis studies. These essential interactions are the ionic interaction with Asp 3.32<sup>1</sup> (basic amine, positive ionisable feature), a  $\pi$

<sup>1</sup> Numbers indicate the Ballesteros-Weinstein numbering scheme where the first digit represents the transmembrane helix (TM) number followed by the position relative to the most conserved residue in each TM, assigned number 50. Numbers decrease towards the N-terminus.

**Table 7** Experimentally determined affinity and selectivity of compounds at  $\alpha_{1A}$ -AR,  $\alpha_{1B}$ -AR and 5-HT<sub>1A</sub>-R

Compound	$\alpha_{1A}$ -AR			$\alpha_{1B}$ -AR			5-HT <sub>1A</sub> -R			Selectivity (fold) <sup>c</sup>	
	pK <sub>i</sub> <sup>a</sup>	K <sub>i</sub> <sup>b</sup> (nM)	n	pK <sub>i</sub> <sup>a</sup>	K <sub>i</sub> <sup>b</sup> (nM)	n	pK <sub>i</sub> <sup>a</sup>	K <sub>i</sub> <sup>b</sup> (nM)	n	$\alpha_{1A}/\alpha_{1B}$	$\alpha_{1A}/5\text{-HT}_{1A}$
5-Methylurapidil ( <b>5</b> )	9.16 ± 0.12	0.7	3	6.84 ± 0.11*	145	3	9.76 ± 0.12	0.2	4	200	0.3
BMY7378 ( <b>47</b> )	6.24 ± 0.12	590	3	6.78 ± 0.10	168	3	8.52 ± 0.12*	3	4	0.3	0.005
Tamsulosin ( <b>26</b> )							9.88 ± 0.07	0.1	4		
NSC 134750 ( <b>48</b> )	5.64 ± 0.08	2,270	3	5.17 ± 0.12	6,700	3	5.68 ± 0.07	2,090	4	3	1
Tripos 01572 ( <b>49</b> )							5.84 ± 0.10	1,510	4		
Tripos 09931 ( <b>50</b> )							4.66 ± 0.19	21,900	4		
NSC 71286 ( <b>51</b> )	6.72 ± 0.19	192	3	5.31 ± 0.30*	4,880	4	6.71 ± 0.09	196	3	26	1
NSC 135759 ( <b>52</b> )	3.60 ± 0.17	250,000	3	<3	>1 mM	4	NB	NB	3	>4	
NSC 276751 ( <b>53</b> )	4.79 ± 0.20	16,200	3	4.94 ± 0.10	11,600	4	<4	>100 μM	3	0.7	>6
NSC 406293 ( <b>54</b> )	5.00 ± 0.10	10,300	4	4.80 ± 0.15	15,800	4	4.39 ± 0.26	40,800	3	2	4
NSC 134753 ( <b>55</b> )	5.11 ± 0.03	7,730	3	5.56 ± 0.08	2,780	3	6.52 ± 0.19*	303	3	0.4	0.04
NSC 56628 ( <b>56</b> )	4.47 ± 0.08	33,700	3	4.24 ± 0.10	58,200	3	5.49 ± 0.19*	3,200	4	2	0.1
NSC 97911 ( <b>57</b> )	6.68 ± 0.20	209	3	6.39 ± 0.25	410	4	5.10 ± 0.19*	7,860	4	2	38

*n* number of experiments, each performed in triplicate NB indicates no binding detected up to 1 mM

\* Significant differences from the  $\alpha_{1A}$ -AR ( $p < 0.05$ )

<sup>a</sup> LogK<sub>i</sub> ± SEM, <sup>b</sup> inhibition constants are the antilog of mean pK<sub>i</sub>. <sup>c</sup> 1/ratio of K<sub>i</sub> values

interaction with Phe 6.52 (aromatic or hydrophobic feature) and a hydrogen bond between an acceptor and Ser 5.42 [13, 51].

These features were also observed in previously developed 5-HT<sub>1A</sub>-R pharmacophores [33, 52]. In the pharmacophore developed by Weber et al. [33], the amine, HBA and aromatic features were arranged in a linear fashion, and this resembles the arrangement we found in our agonist pharmacophore (Fig. 1a) with ligands fitted in a fairly extended conformation. The antagonist pharmacophore we have constructed (Fig. 1b) is much more crowded with ligands fitted in a bent conformation and resembles more that made by Franchini and colleagues [52], using aryl-piperazine based ligands. In their pharmacophore the piperazine ring adopts a chair conformation perpendicular to the hydrophobic moiety in order to fit the amine feature. Their pharmacophore also suggests that the HBA is located in close proximity to a hydrophobic group, as occurs in both our pharmacophores. Additionally, their pharmacophore demonstrates the necessity for a second HBA feature, an observation also made in structure–activity studies using arylpiperazine and tetrahydropyridylindole derivatives [53]. Other such studies also suggest that the  $\alpha_1$ -AR binding pocket may be more hydrophobic, and the 5-HT<sub>1A</sub>-R pocket more polar, so that  $\alpha_1$ -AR selectivity can be enhanced by removal of charged nitrogen atoms in heterocycles [54], and conversely, increasing the polarity of a ligand has been demonstrated to enhance its 5-HT<sub>1A</sub>-R

selectivity [55]. However, as these studies were restricted in terms of chemical diversity, it could be postulated that not all classes of 5-HT<sub>1A</sub>-R ligands form this second hydrogen bond in the same fashion, hence a second hydrogen bonding feature was not observed in our pharmacophores.

We expand on these previous studies by investigating steric effects, and find large but different sets of excluded volumes for both the agonist and antagonist pharmacophores, as well as very different fitted conformations of ligands to the two pharmacophores. This suggests steric factors may have a large impact on the efficacy of a ligand at the 5-HT<sub>1A</sub>-R. This observation has been made previously in structure–activity studies, whereby the stereochemistry of a single chiral centre can determine whether a compound acts as an agonist or antagonist at the 5-HT<sub>1A</sub>-R [56, 57]. Collectively, this suggests that both agonists and antagonists of the 5-HT<sub>1A</sub>-R are structurally quite similar and of a similar size. This is in marked contrast to  $\alpha_1$ -AR ligands, where there is a distinct difference between agonists which are small in comparison to antagonists, which are comparable in size to 5-HT<sub>1A</sub>-R ligands [14]. However, it also appears from our pharmacophores that, despite their size, the antagonists access a smaller, contracted binding pocket when compared to the agonists. This is in contrast to findings comparing the agonist and antagonist binding pockets in crystal structures of the  $\beta_2$  adrenoceptor, where the agonist binding pocket is the smaller, more contracted one [58].

To test the ability of the newly constructed pharmacophores to predict 5-HT<sub>1A</sub>-R affinity, six compounds belonging to a number of structural classes were mapped to each pharmacophore and their affinity predicted (Table 4). These included known  $\alpha_1$ -AR ligands with 5-HT<sub>1A</sub>-R affinity (BMY7378, 5-methylurapidil, tamsulosin), and novel experimental compounds known to have  $\alpha_1$ -AR affinity (compounds (48)–(50)). The in vitro affinity of these compounds is generally not estimated well by the pharmacophores (mostly underestimated, but this is an artefact of the way the predictions were made; see “Methods and results”). The predictions from the 5-HT<sub>1A</sub>-R agonist and antagonist pharmacophores differ widely for most compounds, except for tamsulosin and BMY7378, with the better fit always to the appropriate pharmacophore for the known compounds. On the other hand, the in vitro affinities of the new hits for the adrenoreceptors are mostly overestimated by the pharmacophores. The 5-HT<sub>1A</sub>-R affinities of these compounds were determined in this work (Table 7), and (48) was predicted very well, whereas (49) and (50) were grossly over predicted. The affinities of (48) for the  $\alpha_1$ -AR subtypes had previously [30] been determined for rodent receptors, but were found to be similar for human receptors in this work (Tables 4, 7).

Clearly, as was expected and was discussed in our earlier papers [29, 30], the pharmacophores are not able to estimate affinities correctly. They are, however, often able to estimate selectivities and relative affinities (see “Results”, Tables 5, 7), but we found them most useful for in silico screening.

The application of ligand-based pharmacophores as a virtual screening tool is more a qualitative approach; whereby if a compound is capable of mapping all pharmacophore features, then there is a significantly high probability that it has micromolar activity. Whilst if more than one feature is missed in mapping, the compound almost certainly has no activity at that target. Previous studies tend to make no mention of predicted values; typical procedure rather is to subject the top hits to single dose testing in vitro at a concentration of  $\sim 100$   $\mu$ M and then determine the affinity of those hits that show activity at this level [59, 60]. Furthermore, the affinity of the top hits from a chemical compound database almost never exceed low micromolar range at the target of interest [60–62]. Thus it was somewhat expected that the experimental compounds would not show the predicted nanomolar affinity for the 5-HT<sub>1A</sub>-R. Also it must be emphasized that these compounds were not designed or chosen to interact with the 5-HT<sub>1A</sub>-R, rather it is the off-target to their intended target, the  $\alpha_1$ -ARs. In the discussion below, we have thus only compared relative fit values of compounds to the pharmacophores (as presented in Figs. 2, 3 and in the “Results” section) to assess predicted selectivities.

We have shown that, as predicted, compound (48), previously identified using our  $\alpha_1$ -AR subtype selective pharmacophores, cannot discriminate between the 5-HT<sub>1A</sub>-R and the  $\alpha_1$ -ARs in terms of affinity. The structurally related compound (55) contains a second tetrahydroisoquinoline group, including a second basic nitrogen. This allows for a variety of different binding modes and potentially accounts for the lack of discrimination observed for this compound. Contrary to predictions, it has higher affinity for the 5-HT<sub>1A</sub>-R than for the  $\alpha_{1B}$ -AR and  $\alpha_{1A}$ -AR, which may also be related to the potentially more polar 5-HT<sub>1A</sub>-R binding pocket discussed above. Three of the remaining new hits ((52), (53), (57)) demonstrate selectivity for  $\alpha_{1A}$ -AR over 5-HT<sub>1A</sub>-R. However, neither of them can discriminate between  $\alpha_{1A}$  and  $\alpha_{1B}$ -AR. This could potentially be related to the fact that for some of these molecules the positive charge (after protonation) is not concentrated on a single nitrogen, but is “smeared out” through several tautomers ((52), (54) and (57)). Compound (56) displays selectivity for 5-HT<sub>1A</sub>-R, but cannot discriminate between  $\alpha_{1A}$  and  $\alpha_{1B}$ -AR. The aminoquinoline moiety in (56) is quite polar, with the nitrogen in the heterocycle also potentially able to be protonated, and as we suggested above for (55), this may explain the high affinity for 5-HT<sub>1A</sub>-R. The same polarity argument may also explain the high 5-HT<sub>1A</sub>-R affinity of (51). This molecule demonstrates the highest  $\alpha_{1A}$ -AR affinity of the test compounds, as well as selectivity over  $\alpha_{1B}$ -AR. However, on top of its high 5-HT<sub>1A</sub>-R affinity (51) contains alkylating groups with unacceptable toxicology issues.

The novel scaffold, compact size, rigidity, and lack of groups associated with potential liability in terms of toxicity of (48) still makes it a desirable lead for drug development. With the information provided by the new pharmacophores,  $\alpha_1$ -AR selectivity may still be achieved for (48) via chemical modification. For example, replacement of the methoxy groups not involved in hydrogen bonding with the  $\alpha_{1A}$ -AR with methyl groups would reduce polarity, which should decrease 5-HT<sub>1A</sub>-R affinity.

## Conclusions

This study has succeeded in constructing pharmacophores, which through the structural diversity of their training sets define the properties of a ligand needed to bind to the 5-HT<sub>1A</sub>-R. Virtual screening and profiling, followed by experimental determination of the affinities of selected hits, has demonstrated that our pharmacophores are capable of identifying unique chemical compounds that fit the requirements to bind to our target, the  $\alpha_{1A}$ -AR, selectively over the off-target, the 5-HT<sub>1A</sub>-R. As predicted, our current lead compound exhibits significant 5-HT<sub>1A</sub>-R affinity. Thus chemical derivatives will need to be synthesized with

increased  $\alpha_1$ -AR affinity, and reduced 5-HT<sub>1A</sub>-R affinity. The insights and knowledge gained through the development of the new 5-HT<sub>1A</sub>-R pharmacophores will greatly aid in this process, and allow the generation of more efficacious and selective ligands.

**Acknowledgments** The authors wish to acknowledge the help of Dr Luke Hunter, School of Chemistry, University of New South Wales, in determining the purity and identity of the test compounds, using the Analytical Centre Facilities. J. Chen wishes to acknowledge financial support through a China Scholarship Council scholarship.

## References

1. Guiard BP, El Mansari M, Merali Z, Blier P (2008) Functional interactions between dopamine, serotonin and norepinephrine neurons: an in vivo electrophysiological study in rats with monoaminergic lesions. *Int J Neuropsychoph* 11(5):625–639
2. Kenakin T (2010) A holistic view of GPCR signaling. *Nat Biotechnol* 28(9):928–929
3. Ahmad N, Keith-Ferris J, Gooden E, Abell T (2006) Making a case for domperidone in the treatment of gastrointestinal motility disorders. *Curr Opin Pharmacol* 6(6):571–576
4. Albert PR, Zhou QY, Vantol HHM, Bunzow JR, Civelli O (1990) Cloning, functional expression, and messenger-RNA tissue distribution of the rat 5-hydroxytryptamine-1a receptor gene. *J Biol Chem* 265(10):5825–5832
5. Gitler MS, Piccio MM, Robillard JE, Jose PA (1991) Characterization of renal alpha-adrenoceptor subtypes in sheep during development. *Am J Physiol* 260(2):R407–R412
6. Langer SZ, Schoemaker H (1989) Alpha-adrenoceptor subtypes in blood-vessels—physiology and pharmacology. *Clin Exp Hypertens A* 11:21–30
7. Auclair AL, Kleven MS, Besnard J, Depoortere R, Newman-Tancredi A (2006) Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT<sub>1A</sub> receptor activation and dopamine D-2 receptor blockade. *Neuropsychopharmacol* 31(9):1900–1909
8. Bantick RA, Deakin JFW, Grasby PM (2001) The 5-HT<sub>1A</sub> receptor in schizophrenia: a promising target for novel atypical neuroleptics? *J Psychopharmacol* 15(1):37–46
9. Christmas TJ, Kirby RS (1991) Alpha-adrenoceptor blockers in the treatment of benign prostatic hyperplasia. *World J Urol* 9(1):36–40
10. Hatzenbuehler NT, Baudy R, Evrard DA, Failli A, Harrison BL, Lenicek S, Mewshaw RE, Saab A, Shao U, Sze J, Zhang M, Zhou D, Chlenov M, Kagan M, Golembieski J, Hornby G, Lai M, Smith DL, Sullivan KM, Schechter LE, Andree TH (2008) Advances toward new antidepressants with dual serotonin transporter and 5-HT<sub>1A</sub> receptor affinity within a class of 3-aminochroman derivatives. Part 2. *J Med Chem* 51(21):6980–7004
11. Jain KS, Bariwal JB, Kathiravan MK, Phoujdar MS, Sahne RS, Chauhan BS, Shah AK, Yadav MR (2008) Recent advances in selective alpha<sub>1</sub>-adrenoreceptor antagonists as antihypertensive agents. *Bioorgan Med Chem* 16(9):4759–4800
12. Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, Arima K, Sugimura Y (2008) Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. *Int J Cancer* 122(2):444–451
13. Nowak M, Kolaczowski M, Pawlowski M, Bojarski AJ (2006) Homology modeling of the serotonin 5-HT<sub>1A</sub> receptor using automated docking of bioactive compounds with defined geometry. *J Med Chem* 49(1):205–214
14. Sorbi C, Franchini S, Tait A, Prandi A, Gallesi R, Angeli P, Marucci G, Pirona L, Poggessi E, Brasili L (2009) 1,3-Dioxolane-based ligands as rigid analogues of naftopidil: structure-affinity/activity relationships at alpha<sub>1</sub> and 5-HT<sub>1A</sub> receptors. *Chem Med Chem* 4(3):393–399
15. Teeter MM, Froimowitz M, Stec B, Durand CJ (1994) Homology modeling of the dopamine D-2 receptor and its testing by docking of agonists and tricyclic antagonists. *J Med Chem* 37(18):2874–2888
16. Keiser MJ, Setola V, Irwin JJ, Lagner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijter MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KLH, Edwards DD, Shoichet BK, Roth BL (2009) Predicting new molecular targets for known drugs. *Nature* 462(7270):175–181
17. Taguchi K, Yang M, Goepel M, Michel MC (1998) Comparison of human alpha<sub>1</sub>-adrenoceptor subtype coupling to protein kinase C activation and related signalling pathways. *N-S Arch Pharmacol* 357(2):100–110
18. Michel MC, Vrydag W (2006) Alpha<sub>1</sub>-, alpha<sub>2</sub>- and beta-adrenoceptors in the urinary bladder, urethra and prostate. *Brit J Pharmacol* 147:S88–S119
19. Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA (1999) Subtype specific regulation of human vascular alpha<sub>1</sub>-adrenergic receptors by vessel bed and age. *Circulation* 100(23):2336–2343
20. Koshimizu T, Tanoue A, Hirasawa A, Yamauchi J, Tsujimoto G (2003) Recent advances in alpha<sub>1</sub>-adrenoceptor pharmacology. *Pharmacol Therapeut* 98(2):235–244
21. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, Dias N (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild-to-moderate essential-hypertension—a double-blind, placebo-controlled dose-response multicenter study. *J Urology* 154(1):110–115
22. Palea S, Chang DF, Rezik M, Regnier A, Lluet P (2008) Comparative effect of alfuzosin and tamsulosin on the contractile response of isolated rabbit prostatic and iris dilator smooth muscles—possible model for intraoperative floppy-iris syndrome. *J Cataract Refr Surg* 34(3):489–496
23. Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T (1999) Naftopidil, a novel alpha<sub>1</sub>-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha<sub>1</sub>-adrenoceptors. *Jpn J Pharmacol* 79(4):447–454
24. Bortolozzi A, Amargos-Bosch M, Toth M, Artigas F, Adell A (2004) In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT<sub>1A</sub> receptor knockout mice. *J Neurochem* 88(6):1373–1379
25. Li Q, Holmes A, Ma L, Van de Kar LD, Garcia F (2004) Medial hypothalamic 5-hydroxytryptamine (5-HT<sub>1A</sub>) receptors regulate neuroendocrine responses to stress and exploratory locomotor activity: application of recombinant adenovirus containing 5-HT<sub>1A</sub> sequences. *J Neurosci* 24(48):10868–10877
26. Monti JM, Jantos H (2003) Differential effects of the 5-HT<sub>1A</sub> receptor agonist flesinoxan given locally or systemically on REM sleep in the rat. *Eur J Pharmacol* 478(2–3):121–130
27. Yu YX, Ramage AG, Koss MC (2004) Pharmacological studies of 8-OH-DPAT-induced pupillary dilation in anesthetized rats. *Eur J Pharmacol* 489(3):207–213
28. Mitra S, Malhotra S, Naruganahalli KS, Chugh A (2007) Role of peripheral 5-HT<sub>1A</sub> receptors in detrusor over activity associated with partial bladder outlet obstruction in female rats. *Eur J Pharmacol* 561(1–3):189–193
29. MacDougall IJA, Griffith R (2006) Selective pharmacophore design for alpha<sub>1</sub>-adrenoceptor subtypes. *J Mol Graph Model* 25(1):146–157

30. Stoddart ES, Senadheera S, MacDougall IJA, Griffith R, Finch AM (2011) A novel structural framework for  $\alpha_{1A/D}$ -adrenoceptor selective antagonists identified using subtype selective pharmacophores. *Plos One* 6(5):e19695
31. Lopez-Rodriguez ML, Morcillo MJ, Fernandez E, Porras E, Orzensanz L, Beneytez ME, Manzanares J, Fuentes JA (2001) Synthesis and structure-activity relationships of a new model of arylpiperazines. 5. Study of the physicochemical influence of the pharmacophore on 5-HT<sub>1A</sub>/ $\alpha_1$ -adrenergic receptor affinity: synthesis of a new derivative with mixed 5-HT<sub>1A</sub>/D-2 antagonist properties. *J Med Chem* 44(2):186–197
32. Strappaghetti G, Mastrini L, Lucacchini A, Giannaccini G, Betti L, Fabbri L (2008) Synthesis and biological affinity of new imidazo- and indol-arylpiperazine derivatives: further validation of a pharmacophore model for  $\alpha_1$ -adrenoceptor antagonists. *Bioorg Med Chem Lett* 18(18):5140–5145
33. Weber KC, Salum LB, Honorio KM, Andricopulo AD, da Silva ABF (2010) Pharmacophore-based 3D QSAR studies on a series of high affinity 5-HT<sub>1A</sub> receptor ligands. *Eur J Med Chem* 45(4):1508–1514
34. Spitzer GM, Heiss M, Mangold M, Mark P, Kirchmair J, Wolber G, Liedl KR (2010) One concept, three implementations of 3D pharmacophore-based virtual screening: distinct coverage of chemical search space. *J Chem Inf Model* 50(7):1241–1247
35. Lopata MA, Cleveland DW, Sollnerwebb B (1984) High-level transient expression of a chloramphenicol acetyl transferase gene by deae-dextran mediated DNA transfection coupled with a dimethylsulfoxide or glycerol shock-treatment. *Nucleic Acids Res* 12(14):5707–5717
36. Perez DM, Piascik MT, Graham RM (1991) Solution-phase library screening for the identification of rare clones—isolation of an  $\alpha_1$ -adrenoceptor cDNA. *Mol Pharmacol* 40(6):876–883
37. Bradford MM (1976) Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. *Anal Biochem* 72(1–2):248–254
38. Li H, Sutter J, Hoffmann R (2000) HypoGen: an automated system for generating 3D predictive pharmacophore models. In: Güner OF (ed) *Pharmacophore perception, development, and use in drug design*, International University Line Biotechnology Series, La Jolla, pp 171–189
39. Chiang YK, Kuo CC, Wu YS, Chen CT, Coumar MS, Wu JS, Hsieh HP, Chang CY, Jseng HY, Wu MH, Leou JS, Song JS, Chang JY, Lyu PC, Chao YS, Wu SY (2009) Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. *J Med Chem* 52(14):4221–4233
40. Ahmed M, Hossain M, Bhuiyan MA, Ishiguro M, Tanaka T, Muramatsu I, Nagatomo T (2008) Mutational analysis of the  $\alpha_{1A}$ -adrenergic receptor binding pocket of antagonists by radioligand binding assay. *Biol Pharm Bull* 31(4):598–601
41. Cavalli A, Fanelli F, Taddei C, DeBenedetti PG, Cotecchia S (1996) Amino acids of the  $\alpha_{1B}$ -adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes. *Febs Lett* 399:9–13
42. Olivier B, Soudijn W, van Wijngaarden I (1999) The 5-HT<sub>1A</sub> receptor and its ligands: structure and function. *Prog Drug Res* 52:103–165
43. Ryan AJ, Baker BR, Vermeulen NMJ (1970) Irreversible enzyme inhibitors. CLXXIV. Metabolism of 4-[p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)hydrocinnamido]-o-toluenesulfonyl fluoride (NSC-113423), and active-site-directed irreversible inhibitor of dihydrofolate reductase. *J Med Chem* 13(6):1140–1142
44. Adams A, Jarrott B, Elmes BC, Denny WA, Wakelin LP (1985) Interaction of DNA-intercalating antitumor agents with adrenoceptors. *Mol Pharmacol* 27(4):480–491
45. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA (1997) Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned  $\alpha_{1A}$ -adrenergic receptor subtypes. *Prostate* 33(1):55–59
46. Sharif NA, Drace CD, Williams GW, Crider JY (2004) Cloned human 5-HT<sub>1A</sub> receptor pharmacology determined using agonist binding and measurement of cAMP accumulation. *J Pharm Pharmacol* 56(10):1267–1274
47. Pulito VL, Li XB, Varga SS, Mulcahy LS, Clark KS, Halbert SA, Reitz AB, Murray WV, Jolliffe LK (2000) An investigation of the uroselective properties of four novel  $\alpha_{1A}$ -adrenergic receptor subtype-selective antagonists. *J Pharmacol Exp Ther* 294(1):224–229
48. Quaglia W, Santoni G, Pigni M, Piergentili A, Gentili F, Buccioni A, Mosca M, Lucciarini R, Amantini C, Nabissi ML, Ballarini P, Poggesi E, Leonardi A, Giannella M (2005) Structure-activity relationships in 1,4-benzodioxan-related compounds. 8. {2-[2-(4-chlorobenzoyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clophenphendioxan) as a tool to highlight the involvement of  $\alpha_{1D}$ - and  $\alpha_{1B}$ -adrenoceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation. *J Med Chem* 48(24):7750–7763
49. Benning CM, Kyprianou N (2002) Quinazoline-derived  $\alpha_1$ -adrenoceptor antagonists induce prostate cancer cell apoptosis via an  $\alpha_1$ -adrenoceptor-independent action. *Cancer Res* 62(2):597–602
50. Andersson KE, Wyllie MG (2003) Ejaculatory dysfunction: why all  $\alpha$ -blockers are not equal. *BJU Int* 92(9):876–877
51. Chanda PK, Minchin MCW, Davis AR, Greenberg L, Reilly Y, Mcgregor WH, Bhat R, Lubeck MD, Mizutani S, Hung PP (1993) Identification of residues important for ligand-binding to the human 5-hydroxytryptamine-1A serotonin receptor. *Mol Pharmacol* 43(4):516–520
52. Franchini S, Prandi A, Sorbi C, Tait A, Baraldi A, Angeli P, Buccioni M, Cilia A, Poggesi E, Fossa P, Brasili L (2010) Discovery of a new series of 5-HT<sub>1A</sub> receptor agonists. *Bioorg Med Chem Lett* 20(6):2017–2020
53. Gaillard P, Carrupt PA, Testa B, Schambel P (1996) Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT<sub>1A</sub> receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models. *J Med Chem* 39(1):126–134
54. Lopez-Rodriguez ML, Ayala D, Viso A, Benhamu B, de la Pradilla RF, Zarza F, Ramos JA (2004) Synthesis and structure-activity relationships of a new model of arylpiperazines. Part 7: study of the influence of lipophilic factors at the terminal amide fragment on 5-HT<sub>1A</sub> affinity/selectivity. *Bioorgan Med Chem* 12(6):1551–1557
55. Franchini S, Prandi A, Baraldi A, Sorbi C, Tait A, Buccioni M, Marucci G, Cilia A, Pirona L, Fossa P, Cichero E, Brasili L (2010) 1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: structure-affinity/activity relationship at  $\alpha_1$ -adrenoceptor subtypes and at 5-HT<sub>1A</sub> receptors. *Eur J Med Chem* 45(9):3740–3751
56. Sabb AL, Vogel RL, Kelly MG, Palmer Y, Smith DL, Andree TH, Schechter LE (2001) 1,2,5-thiadiazole derivatives are potent and selective ligands at human 5-HT<sub>1A</sub> receptors. *Bioorg Med Chem Lett* 11(8):1069–1071
57. Shen ZQ, Ramamoorthy PS, Hatzenbuehler NT, Evrard DA, Childers W, Harrison BL, Chlenov M, Hornby G, Smith DL, Sullivan KM, Schechter LE, Andree TH (2010) Synthesis and structure-activity relationship of novel lactam-fused chroman derivatives having dual affinity at the 5-HT<sub>1A</sub> receptor and the serotonin transporter. *Bioorg Med Chem Lett* 20(1):222–227
58. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp

- A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK (2011) Structure of a nanobody-stabilized active state of the  $\beta_2$  adrenoceptor. *Nature* 469(7329):175–180
59. Doddareddy MR, Choo H, Cho YS, Rhim H, Koh HY, Lee JH, Jeong SW, Pae AN (2007) 3D pharmacophore based virtual screening of T-type calcium channel blockers. *Bioorgan Med Chem* 15(2):1091–1105
  60. Ryu K, Kim ND, Il Choi S, Han CK, Yoon JH, No KT, Kim KH, Seong BL (2009) Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. *Bioorgan Med Chem* 17(8):2975–2982
  61. Al-Sha'er MA, Taha MO (2010) Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. *Eur J Med Chem* 45(9):4316–4330
  62. Aparoy P, Reddy KK, Kalangi SK, Reddy TC, Reddanna P (2010) Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors. *Bioorg Med Chem Lett* 20(3):1013–1018
  63. Linnanen T, Brisander M, Unelius L, Sundholm G, Hacksell U, Johansson AM (2000) Derivatives of (R)-1,11-methyleneaporphine: synthesis, structure, and interactions with G-protein coupled receptors. *J Med Chem* 43(7):1339–1349
  64. Newman-Tancredi A, Martel JC, Assie MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B, Cussac D (2009) Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT<sub>1A</sub> receptor agonist. *Br J Pharmacol* 156(2):338–353
  65. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrielle L, Audinot V, Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT<sub>1A</sub> receptors: a [<sup>35</sup>S]GTP gamma S binding study. *Eur J Pharmacol* 355(2–3):245–256
  66. Maurel JL, Autin JM, Funes P, Newman-Tancredi A, Colpaert F, Vacher B (2007) High-efficacy 5-HT<sub>1A</sub> Agonists for antidepressant treatment: a renewed opportunity. *J Med Chem* 50(20):5024–5033
  67. Zhou DH, Hatzenbuehler NT, Gross JL, Harrison BL, Evrard DA, Chlenov M, Golembieski J, Hornby G, Schechter LE, Smith DL, Andree TH, Stack GP (2007) Novel pyridyl-fused 3-amino chroman derivatives with dual action at serotonin transporter and 5-HT<sub>1A</sub> receptor. *Bioorg Med Chem Lett* 17(11):3117–3121
  68. Paluchowska MH, Bugno R, Duszynska B, Tatarczynska E, Nikiforuk A, Lenda T, Chojnacka-Wojcik E (2007) The influence of modifications in imide fragment structure on 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines. *Bioorgan Med Chem* 15(22):7116–7125
  69. Picard M, Morisset S, Cloix JF, Bizot JC, Guerin M, Beneteau V, Guillaumet G, Hevor TK (2010) Pharmacological, neurochemical, and behavioral profile of Jb-788, a new 5-HT<sub>1A</sub> agonist. *Neuroscience* 169(3):1337–1346
  70. Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE (2006) WAY-100635 is a potent dopamine D4 receptor agonist. *Psychopharmacology* 188(2):244–251
  71. Ward SE, Eddershaw PJ, Scott CM, Gordon LJ, Lovell PJ, Moore SH, Smith PW, Starr KR, Thewlis KM, Watson JM (2008) Discovery of potent, orally bioavailable, selective 5-HT<sub>1A/B/D</sub> receptor antagonists. *J Med Chem* 51(10):2887–2890
  72. Kuo GH, Prouty C, Murray WV, Pulito V, Jolliffe L, Cheung P, Varga S, Evangelisto M, Wang J (2000) Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha<sub>1A</sub>-adrenergic receptor antagonists. *J Med Chem* 43(11):2183–2195
  73. Dunlop J, Zhang Y, Smith DL, Schechter LE (1998) Characterization of 5-HT<sub>1A</sub> receptor functional coupling in cells expressing the human 5-HT<sub>1A</sub> receptor as assessed with the cytosensor microphysiometer. *J Pharmacol Toxicol Methods* 40(1):47–55
  74. Krushinski JH, Schaus JM, Thompson DC, Calligaro DO, Nelson DL, Luecke SH, Wainscott DB, Wong DT (2007) Indoloxypipranolamine analogues as 5-HT<sub>1A</sub> receptor antagonists. *Bioorg Med Chem Lett* 17(20):5600–5604
  75. Dessalew N (2008) QSAR study on dual 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> antagonists: an insight into the structural requirement for antidepressant activity. *Arch Pharm* 341(5):314–322
  76. Serafinowska HT, Blaney FE, Lovell PJ, Merlo GG, Scott CM, Smith PW, Starr KR, Watson JM (2008) Novel 5-HT<sub>1A/1B/1D</sub> receptors antagonists with potent 5-HT reuptake inhibitory activity. *Bioorg Med Chem Lett* 18(20):5581–5585
  77. Evrard DA, Zhou P, Yi SY, Zhou DH, Smith DL, Sullivan KM, Hornby GA, Schechter LE, Andree TH, Mewshaw RE (2005) Studies towards the next generation of antidepressants. Part 4: derivatives of 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT<sub>1A</sub> receptor. *Bioorg Med Chem Lett* 15(4):911–914
  78. Saussy DL Jr, Goetz AS, Queen KL, King HK, Lutz MW, Rimele TJ (1996) Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. *J Pharmacol Exp Ther* 278(1):136–144